What is ESLA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ESLA?

P/E (TTM) is n/a and 52-week range is $0.36 to $3.15 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ESLA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ESLA?

The company profile lists net income (TTM) near $-11M, EPS (TTM) near $-0.25 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Estrella Immunopharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Emeryville, California, US, 43M shares outstanding, ISIN US2975841048 when available from company profile and filing metadata.

Estrella Immunopharma Inc

$ESLA

Health Care · Biotechnology

IR Run Scenarios

$0.41

-1.80%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company is headquartered in Emeryville, California. The company went IPO on 2021-07-19. The firm is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The firm is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The firm is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).

Website

www.estrellabio.com/

IPO

2021-07-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)